ImmunityBio: D. Boral Capital maintains a 'Buy' Rating, The Target Price is $24

D. Boral Capital maintains 'Buy' rating on ImmunityBio(IBRX).

The target price is unchanged and still at 24 .

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2026-01-16	D. Boral Capital	Maintains	Buy	Buy	$24	$24
2026-01-13	D. Boral Capital	Maintains	Buy	Buy	$24	$24

[Recent Earning Results] Immunitybio posted the Q3 of its 2025 financial results on 11/5/2025, reporting total revenue of USD 75.00 million in the first three quarters, up 942.72% from USD 7.19 million year over year, reporting net income of USD -289.51 million in the first three quarters, narrowing 18.32% from USD -354.47 million year over year.

[Company Profile] ImmunityBio, Inc. was incorporated in Illinois on October 7, 2002 under the name ZelleRx Corporation. On January 22, 2010, the Company changed its name to Conkwest, Inc. ImmunityBio is a leading late-stage immunotherapy company activating both the innate and adaptive immune system to treat serious unmet needs within oncology and infectious diseases. The company is a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, memory NK cells , together with a comprehensive platform of antibody cytokine fusion proteins, albumin bound chemo-immunomodulators and vaccine vectors. By combining these NK, macrophage and T cell activation platforms, the company believe ImmunityBio leads the field of immunotherapy with late-stage clinical development across multiple tumor types and infectious diseases.